For example, in ovarian cancer patients, ETBR expression correlates with low tumor infiltrating lymphocytes, and experimental models have shown that pharmacological blockade of ETBR with BQ-788 enhances T cell infiltration into tumors by modifying the endothelial barrier via a NO- and ICAM1-dependent mechanism (91). Here, EDNRB is linked to neoplasm.